EUVIMED · CrossrefZeitschrift
Future Oncology
ISSN 1479-6694 · Informa UK Limited
Neueste Artikel
Health-related quality of life, symptoms, and burden in metastatic urothelial cancer in Europe: a real-world survey
Transfusion-related cost and time burden offsets associated with pacritinib versus best available therapy in patients with myelofibrosis: an economic evaluation based on the PERSIST-2 trial
Diagnostic performance of MRI, endorectal ultrasound, and FAPI PET/MRI for identifying pathological complete response after short-course radiotherapy and chemoimmunotherapy in locally advanced rectal cancer: a retrospective study
Stereotactic ablative radiotherapy and immunotherapy in metastatic colorectal cancer: overcoming immune resistance through immune priming
PADL1NK-005 study design: a phase III trial of fetrastobart vedotin (Fetra-V) vs docetaxel in patients with previously treated tumor PD-L1–positive NSCLC
Treatment outcomes of tucatinib in combination with trastuzumab and pertuzumab as a maintenance therapy for people with HER2+ metastatic breast cancer: a plain language summary of findings from HER2CLIMB-05
Efficacy and safety of Disitamab Vedotin (RC48-ADC) monotherapy versus combination therapy with immune checkpoint inhibitors in solid tumors: a systematic review and meta-analysis
Zanidatamab in the treatment of esophagogastric adenocarcinoma
Study design of the phase III ADELA trial of elacestrant with or without everolimus in ESR1 -mutated ER+/HER2– advanced breast cancer after progression on endocrine therapy plus a CDK4/6 inhibitor
Falcon – multicancer early detection (MCED) real-world evidence (RWE) registry
Protocol for a multicenter prospective phase II trial of adjuvant tislelizumab combined with S-1 in subjects with residual primary lesions and node-negative esophageal squamous cell carcinoma (PPIO-008)
Targeting menin dependency in acute leukemias: the role of revumenib in NPM1-mutated and KMT2A/NUP98-rearranged disease
Post-ASCO 2026: resident-led highlights of the most clinically relevant studies in genitourinary oncology
Gedatolisib for the treatment of hormone receptor-positive/HER2-negative advanced breast cancer: a European perspective
Perioperative tislelizumab plus neoadjuvant chemotherapy for patients with resectable non–small cell lung cancer: patient-reported outcomes in the RATIONALE-315 trial
Treatment patterns and characteristics of Chinese patients with advanced or resectable melanoma: a multicenter retrospective study
Is IMvigor011 a conventional adjuvant trial or a ctDNA-triggered preemptive treatment strategy?
Treatment outcomes and quality of life with palbociclib in patients with advanced breast cancer who also have other medical conditions: a plain language summary of findings from POLARIS
Study protocol of a prospective, non-interventional cohort study evaluating the benefits of transjugular intrahepatic portosystemic shunt in patients with hepatocellular carcinoma receiving first-line atezolizumab plus bevacizumab (NISTIPS TRITICC-4, IKF092)
Interleukin-6 as a prognostic biomarker in hepatocellular carcinoma treated with systemic therapy: a systematic review and meta-analysis
Durvalumab plus etoposide–carboplatin for advanced digestive neuroendocrine carcinoma: a phase III trial (JCOG2107E)
Plain language summary: comparing ivonescimab plus chemotherapy with placebo plus chemotherapy in people with advanced EGFR-mutated non–small cell lung cancer (NSCLC) whose disease worsened on EGFR-TKI treatment in the HARMONi study
Plain language summary of the ReNeu study: a study of mirdametinib for adults and children with neurofibromatosis type 1 (NF1) who have plexiform neurofibromas
Beyond survival: advancing psycho-oncology research on fear of recurrence or progression
Review of evidence and future directions following the TUBA study: a long-term prospective preference study comparing risk-reducing salpingectomy with delayed oophorectomy to salpingo-oophorectomy
Phase 1 study of OX40 agonist ABBV-368 as monotherapy or in combination with budigalimab in advanced solid tumors
Is neoadjuvant therapy redefining the surgeon’s role in melanoma?
Tissue-based PEG10 expression as an exploratory biomarker associated with first-line R-CHOP treatment outcome in diffuse large B-cell lymphoma
A plain language summary of results from the NeoADAURA study: treatment with osimertinib before surgery for patients with EGFR-mutated non-small cell lung cancer that can be surgically removed
DUBHE-H-308 study protocol: rationale and adaptive design of a randomized, open-label, seamless phaseII/III trial of iparomlimab and tuvonralimab (QL1706)-based regimens versus sintilimab plus bevacizumab as first-line treatment for advanced hepatocellular carcinoma
EUVIMED